78932-95-3 Usage
Uses
Used in Pharmaceutical Industry:
1-(4-phenylmethoxyphenyl)-N-[4-(4-phenylpiperazin-1-yl)phenyl]methanimine is used as a potential therapeutic agent for various applications due to its ability to interact with biological systems. The presence of a piperazine ring, a phenyl group, and a methoxy group in its structure may contribute to its potential therapeutic effects.
Used in Chemical Research:
1-(4-phenylmethoxyphenyl)-N-[4-(4-phenylpiperazin-1-yl)phenyl]methanimine is used as a subject of study in chemical research to explore its unique structure, properties, and potential applications. Further research and testing are necessary to fully understand its potential uses and effects in various fields, including pharmaceuticals and drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 78932-95-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,8,9,3 and 2 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 78932-95:
(7*7)+(6*8)+(5*9)+(4*3)+(3*2)+(2*9)+(1*5)=183
183 % 10 = 3
So 78932-95-3 is a valid CAS Registry Number.
InChI:InChI=1/C30H29N3O/c1-3-7-26(8-4-1)24-34-30-17-11-25(12-18-30)23-31-27-13-15-29(16-14-27)33-21-19-32(20-22-33)28-9-5-2-6-10-28/h1-18,23H,19-22,24H2/b31-23+
78932-95-3Relevant academic research and scientific papers
Compounds Acting on CVS : Part I - Synthesis of 1-(p-Substituted-benzylaminophenyl)-4-arylpiperazines
Agarwal, Jagdish C.,Gupta, Y. K.,Bhargava, K. P.,Shanker, K.
, p. 512 - 514 (2007/10/02)
1-(p-Nitrophenyl)-4-arylpiperazines (II), prepared by the reaction of various arylpiperazines with p-chloronitrobenzene, on reduction with Raney nickel give the corresponding 1-(p-aminophenyl)-4-arylpiperazines (III) which are converted into 1-(p-arylideneaminophenyl)-4-arylpiperazines (IV) by condensation with appropriate araldehydes.Reduction of IV with Pd/C im DMF furnishes the title compounds.Some of these compounds have been found to possess marked cardiovascular activity.Compound IVk exhibits maximum hypotensive activity (38.2 percent) and blocks the carotid occlu-sion response without affecting noradrenaline response indicating a neural (central/peripheral) origin for the hypotensive action.
